CellAegis Devices

OverviewSuggest Edit

CellAegis Devices offers autoRIC, an automated non-invasive device that provides point-of-care delivery of remote ischemic conditioning. The autoRIC Device is intended to provide remote ischemic conditioning to adult patients over 18 years of age undergoing cardiothoracic surgery or interventional cardiothoracic procedures or patients with evolving myocardial infarction. The autoRIC Device is highly portable and time‐efficient, delivering four cycles of simple‐to-administer treatment in less than 40 minutes, freeing up valuable healthcare resources. Device operation is simple and compatible with current standard‐of‐care treatments. RIC delivery is consistent, reliable, and cost-effective.

TypePrivate
Websitecellaegis.com

Recent NewsAll News

Latest Updates

Employees (est.) (Sep 2019)13

Key People/Management at CellAegis Devices

Rocky Ganske

Rocky Ganske

CEO
Brian Fielding

Brian Fielding

CFO
Vera Belaoussoff

Vera Belaoussoff

VP, Clinical and Corporate Development
Michaela Shaw

Michaela Shaw

Quality & Regulatory Affairs Manager
Show more

CellAegis Devices Office Locations

CellAegis Devices has offices in Palo Alto and Mississauga
Mississauga, CA
6711 Mississauga Rd #109
Palo Alto, US
288 Hamilton Ave
Palo Alto, US
228 Hamilton Ave 3rd Floor
Show all (3)

CellAegis Devices Financials and Metrics

Summary Metrics

CellAegis Devices total Funding

$9.5 m

CellAegis Devices latest funding size

$9.50 m

Time since last funding

3 years ago

CellAegis Devices investors

Broadview Ventures, CTI Life Sciences Fund, MaRS Catalyst Fund
CellAegis Devices's latest funding round in March 2017 was reported to be $9.5 m. In total, CellAegis Devices has raised $9.5 m
Show all financial metrics

CellAegis Devices Online and Social Media Presence

CellAegis Devices's Trends

Embed Graph

CellAegis Devices Blogs

September 11, 2018

autoRIC® Trial Enrollment Complete in N. America

CellAegis Announces Completion of Patient Enrollment in First North American Study for Innovative Heart Attack Therapy Using autoRIC® TORONTO, Ontario, September 11, 2018 – CellAegis Devices […]
September 11, 2018

autoRIC® Trial Enrollment Complete in North America

CellAegis Announces Completion of Patient Enrollment in First North American Study for Innovative Heart Attack Therapy Using autoRIC® The post <span style="text-transform:lowercase">auto</span>RIC<sup>®</sup> Trial Enrollment Complete in North America appeared first on CellA…
June 14, 2018

Enrollment Completed in ERIC-PPCI Hospital Trial

CellAegis Announces Completion of Patient Enrollment in UK Investigator Sponsored Clinical Trial using autoRIC® Device TORONTO, Canada, June 14, 2018 – CellAegis Devices Inc. (“CellAegis” or […]

 CellAegis Devices Frequently Asked Questions

  • Who are CellAegis Devices key executives?

    CellAegis Devices's key executives are Rocky Ganske, Brian Fielding and Vera Belaoussoff.

  • How many employees does CellAegis Devices have?

    CellAegis Devices has 13 employees.

  • Who are CellAegis Devices competitors?

    Competitors of CellAegis Devices include Bardy Diagnostics, EndoGastric Solutions and Acutus Medical.

  • Where are CellAegis Devices offices?

    CellAegis Devices has offices in Palo Alto and Mississauga.

  • How many offices does CellAegis Devices have?

    CellAegis Devices has 3 offices.